MIVetsCan: Cannabidiol (CBD)-Care Trial
ConditionPain, Chronic
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKevin Boehnke
About this trial
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.
Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.
The study hypotheses:
\- CBD would improve overall pain symptoms compared to placebo
Eligibility criteria
Qualifiers
Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
Armed Services Veteran
All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
Reports moderate to severe chronic pain defined by protocol
Disqualifiers
Not an Armed Services Veteran
Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
Participant reports pregnancy or are nursing
Planning to move out of a state with legal recreational marijuana use during course of study
Trial design
Treatments tested in this trial
- Placebo
- Cannabidiol
Treatment groups
468 Participants
are divided into 2 treatment groupsSponsors and collaborators
Kevin Boehnke
Lead sponsor
University of Michigan
Sponsor institution
Michigan, State of, Licensing and Regulatory Affairs
Collaborator
Source ClinicalTrials.gov